Cargando…
Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
BACKGROUND: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF). Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however, the risk of bleeding and the requirement for regular coagulation monitoring are limiting their use. Apixaban i...
Autores principales: | Stevanović, Jelena, Pompen, Marjolein, Le, Hoa H., Rozenbaum, Mark H., Tieleman, Robert G., Postma, Maarten J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122386/ https://www.ncbi.nlm.nih.gov/pubmed/25093723 http://dx.doi.org/10.1371/journal.pone.0103974 |
Ejemplares similares
-
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2019) -
Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018) -
Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2022) -
Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
por: Hersi, Ahmad S., et al.
Publicado: (2019) -
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017)